Omalizumab scratches the itch for urticaria patients
The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers. (Source: MedWire News - Dermatology)
Source: MedWire News - Dermatology - March 4, 2013 Category: Dermatology Source Type: news
Omalizumab Therapy Could Soon Replace Other, More Toxic Treatments For Chronic, Severe Hives And Itch
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Allergy Source Type: news
Asthma Drug Treats Chronic Hives, Severe Itch
A commonly used asthma drug, omalizumab, has shown to be effective in treating chronic hives and severe, itchy rash in adolescents and adults. The finding came from a new study published in The New England Journal of Medicine after examining the effects of a once-a-month, high-dose injection of omalizumab on 323 subjects at 55 medical centers. The participants had previously been taking standard antihistamine therapy, however, it did not put an end to their underlying, allergy-like response, referred to as chronic spontaneous urticaria or chronic idiopathic urticaria... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Allergy Source Type: news
Chronic hives
Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, demonstrated that omalizumab provided effective treatment in patients with moderate to severe refractory chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with approved antihistamine doses. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
Phase III data for omalizumab in the treatment of chronic idiopathic or spontaneous urticaria
Source: NEJM
Area: News
According to the results of an international, multicentre Phase III study published early online in the New England Journal of Medicine, omalizumab at doses of 150mg and 300mg improved outcomes as reported by patients with chronic idiopathic urticaria who had remained symptomatic despite the use of approved doses of H1-antihistamines.
The authors note that the current first-line treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) is with non-sedating H1-antihistamines; however the majority of patients will not have a full response to this and will req...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
Asthma Drug Curbs Chronic Hives (CME/CE)
SAN ANTONIO (MedPage Today) -- Symptoms of chronic idiopathic urticaria in adults that were unresponsive to antihistamines were significantly reduced with omalizumab, a drug prescribed for persistent allergic asthma. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 25, 2013 Category: Dermatology Source Type: news
ASTERIA II: Omalizumab Calms Itch in Chronic UrticariaASTERIA II: Omalizumab Calms Itch in Chronic Urticaria
The drug currently marketed for the treatment of allergic asthma may have a new use, phase 3 trial results suggest. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Omalizumab Proves Highly Effective in Treating Severe Hives and Itch
Asthma drug found highly effective in treating chronic, severe hives and itch - Omalizumab therapy could soon replace other, more toxic treatments. (Source: Disabled World)
Source: Disabled World - February 24, 2013 Category: Disability Tags: Medical Research Source Type: news
Hives May Be Treated With Asthma Drug, Study Shows
Monthly injections by the drug Xolair significantly reduced hives and itchiness in patients who participated in a trial whose results were published online by The New England Journal of Medicine. (Source: NYT Health)
Source: NYT Health - February 24, 2013 Category: Consumer Health News Authors: By LAURIE TARKAN Tags: WebMD Health Corporation WBMD NASDAQ Allergies Clinical Trials Drugs (Pharmaceuticals) Itching Genentech Inc Novartis AG NVS NYSE Antihistamines Source Type: news
Omalizumab Effective in Treating Chronic Hives
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 24, 2013 Category: Primary Care Tags: Medical News Source Type: news
Xolair treatment for asthma sufferers: Don't scrap asthma jab that saved my son's life
As life-changing drug Xolair is declared not 'cost-effective' by the NHS watchdog, one mother makes an urgent plea. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2013 Category: Consumer Health News Source Type: news
Xolair: Not Just for AsthmaXolair: Not Just for Asthma
Omalizumab isn't just a treatment for asthma. Here is an overview of some of the other conditions for which omalizumab may be useful. Medscape Allergy & Immunology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology Article Source Type: news
